| CTRI Number |
CTRI/2025/03/083537 [Registered on: 26/03/2025] Trial Registered Prospectively |
| Last Modified On: |
24/03/2025 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Biological Stem Cell Therapy Surgical/Anesthesia |
| Study Design |
Randomized, Parallel Group, Placebo Controlled Trial |
|
Public Title of Study
|
To compare the efficacy of platelet-rich plasma versus bone marrow-stem cell instillation in infertile women with decreased ovarian reserve undergoing IVF/ICSI treatment |
|
Scientific Title of Study
|
An open labelled, three armed, randomised placebo
controlled trial to study the effect of intra-ovarian platelet-rich plasma versus autologous adult bone marrow- derived stem cell instillation in poor ovarian responders |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Neena Malhotra |
| Designation |
Professor and HOD, Guide |
| Affiliation |
All India Institute of Medical Sciences, New Delhi |
| Address |
701, 7th floor, Mother and Child block, All India Institute of Medical Sciences
New Delhi DELHI 110029 India |
| Phone |
9891557707 |
| Fax |
|
| Email |
malhotraneena@yahoo.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Neena Malhotra |
| Designation |
Professor and HOD, Guide |
| Affiliation |
All India Institute of Medical Sciences, New Delhi |
| Address |
701, 7th floor, Mother and Child block, All India Institute of Medical Sciences
New Delhi DELHI 110029 India |
| Phone |
9891557707 |
| Fax |
|
| Email |
malhotraneena@yahoo.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Gunupuru Gayatri Swetha |
| Designation |
DM resident, Reproductive Medicine |
| Affiliation |
All India Institute of Medical Sciences, New Delhi |
| Address |
Room no 809, Hostel 19, Masjid moth doctor residential campus, AIIMS
New Delhi DELHI 110049 India |
| Phone |
9966526236 |
| Fax |
|
| Email |
gayatriswethagunupuru@gmail.com |
|
|
Source of Monetary or Material Support
|
| All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India, 110029 |
|
|
Primary Sponsor
|
| Name |
AIIMS New Delhi |
| Address |
All India Institute of Medical Sciences, Ansari nagar East, Sir Aurobindo Marg, New Delhi, India, 110029 |
| Type of Sponsor |
Research institution and hospital |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Neena Malhotra |
All India Institute of Medical sciences |
701, 7th floor, Mother and Child block, All India Institute of Medical Sciences New Delhi DELHI |
9891557707
malhotraneena@yahoo.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institute ethics committee for post graduate research |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: N979||Female infertility, unspecified, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Comparator Agent |
Intra-ovarian saline |
2ml of normal saline injected sub-cortically using a 35cm 17G single- lumen ovum pick-up needle with transvaginal ultrasound guidance under general anaesthesia once between day 6 to day 10 during one month of menstrual cycle |
| Intervention |
Intraovarian autologous adult bone-marrow derived stem-cell |
2ml of autologous adult bone-marrow derived stemcell injected sub-cortically using a 35cm 17G single- lumen ovum pick-up needle with transvaginal ultrasound guidance under general anaesthesia once between day 6 to day 10 during one month of menstrual cycle |
| Intervention |
Intraovarian Platelet rich plasma |
2ml of Platelet rich plasma injected sub-cortically using a 35cm 17G single- lumen ovum pick-up needle with transvaginal ultrasound guidance under general anaesthesia once between day 6 to day 10 during one month of menstrual cycle |
|
|
Inclusion Criteria
|
| Age From |
21.00 Year(s) |
| Age To |
45.00 Year(s) |
| Gender |
Female |
| Details |
1. Poor responder
a. POSEIDON group 3 and 4
(Patient-Oriented Strategy Encompassing IndividualizeD Oocyte Number)
The expected poor responder of any age group with poor ovarian reserve parameters (AFC less than 5 and/or AMH less than 1.2ng/ml) OR
b. Poor ovarian responder: less than or equal to 3 oocytes retrieved in previous IVF cycles
2. Age: 21-45 years old
3. BMI: 18-35 kg/m2
4. Willing to give consent |
|
| ExclusionCriteria |
| Details |
1.Patients with POI, Secondary ovarian failure (e. g., hypothalamic causes, chemotherapy, radiotherapy)
2. FSH more than 12 IU/ml
3. Chronic autoimmune diseases
4. Those with major medical problems such as malignancy, hepatitis
5. Known abnormal karyotyping
6. Ovarian Endometriosis (endometrioma)
7. Prior ovarian surgery
8. Active viral infections
9. Hematologic disorders, haemoglobin level of less than 11.0 g/dL or platelet count of less than 150,000/ul |
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Sequentially numbered, sealed, opaque envelopes |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
1.Number of oocytes retrieved
2.Number of mature oocytes (MII) retrieved |
In one IVF cycle, 3 months after the intervention |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
1. FSH, AMH levels
2. Antral Follicle Count, Ovarian volume
3. Dose of gonadotropins
4. Duration of gonadotropin stimulation
5. Level of E2 on the day of trigger
6. Fertilization rate
7. Cleavage rate
8. Blastulation rate
9. Number of good quality embryos
10. Cycle cancellation rate
11. Clinical pregnancy rate per embryo transfer
12. Cumulative clinical pregnancy rate
13. Safety outcomes (post-procedure)
a. pain
b. bleeding
c. abscess or infection
d. injury to any vital organs
e. allergic reactions
f. anaesthesia- related complications. |
In one IVF cycle, 3 months after the intervention |
|
|
Target Sample Size
|
Total Sample Size="39" Sample Size from India="39"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
15/04/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="2" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Poor ovarian response (POR) to gonadotropin stimulation in an IVF cycle remains one of the challenges faced by infertility experts, world-wide. In the recent years, the numbers of poor ovarian responders, both expected, as well as unexpected, are on the rise. Despite better understanding of Controlled ovarian stimulation (COS), and recent advances in laboratory techniques, the estimated prevalence of poor responders, according to the POSEIDON criteria, is around 40%. Various strategies have been developed to help these couples produce their own genetic offspring, helping women through better regimens for pituitary suppression, increased gonadotropin dosages and the addition of adjuvant agents during ovarian stimulation however, high-level evidence on the ideal protocol or strategies using uniform standards for POR are lacking. Therefore, in pursuit of other effective strategies, the role of intraovarian platelet rich plasma (PRP) and intraovarian stem cell instillation are being extensively studied over the last few years. Autologous platelets are believed to promote the development of isolated human primordial and primary follicles to the pre-antral stage, reduce follicular atresia, restore dormant oocytes, thereby restoring fertility. Although there are currently multiple methods for preparing and injecting PRP, there is still no consensus on the optimal method, and there is still controversy over whether ovarian injection of PRP can improve ovarian function. A few case reports, retrospective and prospective cohort, non-randomised studies suggest that PRP treatment may benefit women with poor ovarian response. But, a couple of RCTs have not shown any significant effect of PRP on the oocyte yield. In a recently published RCT conducted by Barrenetxea et al.,(2024), an increase in the number of retrieved oocytes in both the intraovarian PRP group and intraovarian saline group suggests that, beyond the release of growth factor from platelets, a mechanical effect can play a role. They hypothesised that either delivered platelet factors or a potential mechanical effect could be implicated in promoting follicle reactivation. Stem Cells derived from different sources may have some effect on the rescue of ovary function, such as recovering ovarian sex hormone function, reducing apoptosis of germ cells, and increasing the number of follicles. However, the improved ovarian function after stem-cell transplantation is a complex mix of many unclear factors requiring further investigation including their activation by mechanical stimulation. Recent studies have shown contradictory results in terms of its efficacy. Considering the complexity of an autologous product such as PRP or stem-cell and the need for quality control in clinical applications, the ability to reproduce consistent results must be shown before recommending them in clinical practice. Given this context, to strengthen the evidence in the form of randomised controlled trial, our research question aims to determine whether instilling intraovarian PRP or stem cells or saline leads to improvements in ovarian reserve and IVF outcomes. If found useful, they would signify a paradigm shift in fertility treatment for women with POR.
|